On the other hand, we have recently identified BAR502, a semisynthetic bile acid able to act as a dual FXR and GPBAR1 ligand, as a valuable candidate in the treatment of NASH. Here, GPBAR1 is linked to metabolic dysfunction-associated steatohepatitis.